Literature DB >> 12667667

Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses.

Rika Draenert1, Marcus Altfeld, Christian Brander, Nesli Basgoz, Colleen Corcoran, Alysse G Wurcel, David R Stone, Spyros A Kalams, Alicja Trocha, Marylyn M Addo, Philip J R Goulder, Bruce D Walker.   

Abstract

Increasing efforts are directed towards the development of effective vaccines through induction of virus-specific T cell responses. Although emerging data indicate a significant role of these cells in determining viral set point in infections such as HIV, there is as yet no consensus as to the best methods for assaying the breadth of these responses. In this study, we used sensitive interferon gamma-based intracellular cytokine staining (ICS) and Elispot assays to determine the optimal overlapping peptide set to screen for these responses. Twenty persons with established HIV infection were studied, focusing on responses to the highly immunogenic Nef protein. Six different HIV-1 Nef peptide sets were used, ranging in length from 15 to 20 amino acids (aa), in overlap from 10 to 11 amino acids, and derived from two different B clade sequences. A total of 54 CD8 T cell responses to Nef peptides were found in this cohort, of which only 12 were detected using previously defined Nef optimal epitopes. No single peptide set detected all responses. Though there was a trend of the shorter peptides detecting more CD8 T cell responses than the 20 amino acid long peptides and longer peptides detecting more CD4 T cell responses, neither was statistically significant. There was no difference between an overlap of 10 or 11 amino acids. All responses detected with the six different sets of overlapping peptides were towards the more highly conserved regions of Nef. We conclude that peptides ranging from 15 to 20 amino acids yield similar results in IFN-gamma-based Elispot and ICS assays, and that all are likely to underestimate the true breadth of responses to a given reference strain of virus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667667     DOI: 10.1016/s0022-1759(02)00541-0

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  67 in total

1.  Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles.

Authors:  Pedro A Reche; John-Paul Glutting; Hong Zhang; Ellis L Reinherz
Journal:  Immunogenetics       Date:  2004-09-03       Impact factor: 2.846

2.  Characterization of Nef-CXCR4 interactions important for apoptosis induction.

Authors:  Ming-Bo Huang; Ling Ling Jin; Cleve O James; Mahfuz Khan; Michael D Powell; Vincent C Bond
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

3.  Changes in function of HIV-specific T-cell responses with increasing time from infection.

Authors:  Michel L Ndongala; Philomena Kamya; Salix Boulet; Yoav Peretz; Danielle Rouleau; Cécile Tremblay; Roger Leblanc; Pierre Côté; Jean-Guy Baril; RéJean Thomas; Sylvie Vézina; Mohamed R Boulassel; Jean-Pierre Routy; Rafick P Sékaly; Nicole F Bernard
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

4.  CD8+ TCR Bias and Immunodominance in HIV-1 Infection.

Authors:  Henrik N Kløverpris; Reuben McGregor; James E McLaren; Kristin Ladell; Mikkel Harndahl; Anette Stryhn; Jonathan M Carlson; Catherine Koofhethile; Bram Gerritsen; Can Keşmir; Fabian Chen; Lynn Riddell; Graz Luzzi; Alasdair Leslie; Bruce D Walker; Thumbi Ndung'u; Søren Buus; David A Price; Philip J Goulder
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

5.  Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.

Authors:  Mark J Geels; Sheri A Dubey; Kiersten Anderson; Elly Baan; Margreet Bakker; Georgios Pollakis; William A Paxton; John W Shiver; Jaap Goudsmit
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Identification of human immunodeficiency virus-1 specific CD8+ and CD4+ T cell responses in perinatally-infected infants and their mothers.

Authors:  Sharon Shalekoff; Stephen Meddows-Taylor; Glenda E Gray; Gayle G Sherman; Ashraf H Coovadia; Louise Kuhn; Caroline T Tiemessen
Journal:  AIDS       Date:  2009-04-27       Impact factor: 4.177

7.  Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides.

Authors:  Daniel E Kaufmann; Paul M Bailey; John Sidney; Bradford Wagner; Philip J Norris; Mary N Johnston; Lisa A Cosimi; Marylyn M Addo; Mathias Lichterfeld; Marcus Altfeld; Nicole Frahm; Christian Brander; Alessandro Sette; Bruce D Walker; Eric S Rosenberg
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.

Authors:  Behazine Combadière; Annika Vogt; Brice Mahé; Dominique Costagliola; Sabrina Hadam; Olivia Bonduelle; Wolfram Sterry; Shlomo Staszewski; Hans Schaefer; Sylvie van der Werf; Christine Katlama; Brigitte Autran; Ulrike Blume-Peytavi
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

9.  Unexpected diversity of cellular immune responses against Nef and Vif in HIV-1-infected patients who spontaneously control viral replication.

Authors:  Leandro F Tarosso; Mariana M Sauer; Sabri Sanabani; Maria Teresa Giret; Helena I Tomiyama; John Sidney; Shari M Piaskowski; Ricardo S Diaz; Ester C Sabino; Alessandro Sette; Jorge Kalil-Filho; David I Watkins; Esper G Kallas
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

10.  Primary human immunodeficiency virus type 1-specific CD8+ T-cell responses induced by myeloid dendritic cells.

Authors:  Bonnie A Colleton; Xiao-Li Huang; Nada M Melhem; Zheng Fan; Luann Borowski; Giovanna Rappocciolo; Charles R Rinaldo
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.